Efficacy of the Bactimunal metabiotic (based on Bacillus subtilis) in non-alcoholic fatty liver disease
https://doi.org/10.31146/1682-8658-ecg-216-8-93-99
Abstract
The aim of the study was to evaluate the effectiveness of a metabiotic based on Bacillus subtilis biologically active food supplement “Baktimunal” in the treatment of patients with NAFLD. Materials and methods. Baktimunal was received by 40 patients with NAFLD: 26 (65.0%) women, 14 (35.0%) men, aged 56.09±8.92 years. The diagnosis of NAFLD was verified on the basis of traditional clinical, laboratory and sonographic data. Initially and at the end of therapy, along with functional liver tests, the following indicators were determined: the level of endotoxin in the blood using the test systems “ELISA Kit for Lipopolysaccharide (LPS) Cloud-Clone Corp. USA”, fatty liver index (FLI) and fibrosis index FIB-4. Baktimunal was prescribed 1 capsule 2 times a day for 6 weeks. The control group consisted of 12 healthy donors, their endotoxin level was 0.07±0.05 pg/ml. Results. A positive clinical and laboratory effect of Baktimunal was noted in 32 (80.0%) patients: the level of endotoxin decreased from 0.19±0.06 pg/ml to 0.13±0.05 pg/ml (p<0.05), alanine aminotransferase - from 55.06±22.14 U/l to 38.8±20.49 U/l (p<0.05), glycemia - from 8.34±1.28 mmol/l to 7.42± 1.12 mmol/l (p<0.05), the level of lymphocytes increased from 2.54±0.41x109/l to 3.01±0.58x109/l (p<0.05), monocytes - from 0 .53±0.23x109/l to 0.77±0.19x109/l (p<0.05). There was a trend towards normalization of dyslipidemia, a decrease in FLI and FIB-4. Conclusion. The effectiveness of Baktimunal was noted in 80.0% of NAFLD patients, it was characterized by a decrease in the level of metabolic endotoxicosis, hepatocellular inflammation, glycemia and an increase in innate immunity cells.
About the Authors
O. P. Dudanova
Petrozavodsk State University
Russian Federation
Russian Federation
N. A. Larina
Petrozavodsk State University
Russian Federation
Russian Federation
A. A. Shipovskaya
Petrozavodsk State University
Russian Federation
Russian Federation
I. V. Kurbatova
Institute of Biology of the Karelian Research Centre of the Russian Academy of Sciences
Russian Federation
Russian Federation
References
1. Pezzino S., Sofia M., Mazzone C., Castorina S., Puleo S., Barchitta M. et al. Gut Microbiome in the Progression of NAFLD, NASH and Cirrhosis, and Its Connection with Biotics: A Bibliometric Study Using Dimensions Scientific Research Database. Biology (Basel). 2023;12(5):662. doi: 10.3390/biology12050662.
2. Albillos A., de Gottardi A., Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003.
3. Chu H., Duan Y., Yang L., Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68(2):359-370. doi: 10.1136/gutjnl-2018-316307.
4. Lazebnik L.B., Golovanova E. V., Turkina S. V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л. Б., Голованова Е. В., Туркина С. В. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1): 4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.
5. Bajaj J.S., Ng S. C., Schnabl B. Promises of microbiome-based therapies. Journal of Hepatology. 2022; 76 (6): 1379-1391. doi: 10.1016/j.jhep.2021.12.003.
6. Wang Y., Wang Y., Sun J. The clinical effect of probiotics on patients with non-alcoholic fatty liver disease: a meta-analysis. Bioengineered. 2022;13(7-12):14960-14973. doi: 10.1080/21655979.2023.2185941.
7. Shenderov BA. Metabiotics: novel idea or natural development of probiotic conception. Microb Ecol Health Dis. 2013;24. doi: 10.3402/mehd.v24i0.20399.
8. Shenderov B.A., Tkachenko E. I., Lazebnik L. B., Ardatskaya M. D., Sinitsa A. V., Zakharchenko M. M. Metabiotics - novel technology of protective and treatment of diseases associated with microecological imbalance in human being. Experimental and Clinical Gastroenterology. 2018;(3):83-92. (In Russ.)@@ Шендеров Б. А., Ткаченко Е. И., Лазебник Л. Б., Ардатская М. Д., Синица А. В., Захарченко М. М. Метабиотики - новая технология профилактики и лечения заболеваний, связанных с микроэкологическими нарушениями в организме человека. Экспериментальная и клиническая гастроэнтерология. 2018;151(3): 83-92.
9. Salminen S., Collado M. C., Endo A., Hill C, Lebeer S, Quigley EMM. et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol.2021; 18: 649-667. doi: 10.1038/s41575-021-00440-6.
10. Harte A.L., da Silva N. F., Creely S. J. et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond). 2010;7:15. doi: 10.1186/1476-9255-7-15.
11. Carpino G., Del Ben M., Pastori D. et al. Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology. 2020;72(2):470-485. doi: 10.1002/hep.31056.
12. Baratta F., Pastori D., Bartimoccia S., Cammisotto V., Cocomello N., Colantoni A. et al. Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients. 2020;12(6):1732. doi: 10.3390/nu12061732.
13. Xue L., He J., Gao N., Lu X., Li M., Wu X. et al. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep. 2017;7:45176. doi: 10.1038/srep45176.
14. An L., Wirth U., Koch D., Schirren M., Drefs M., Koliogiannis D. et al. Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. J Gastrointest Surg. 2022;26(3):671-683. doi: 10.1007/s11605-021-05188-7.
15. Bourebaba Y., Marycz K., Mularczyk M., Bourebaba L. Postbiotics as potential new therapeutic agents for metabolic disorders management. Biomedicine & Pharmacotherapy. 2022; 153:113138. doi: 10.1016/j.biopha.2022.113138.
16. de Vos W. M., Tilg H., Van Hul M., Cani P. D. Gut microbiome and health: mechanistic insights. Gut. 2022;71(5):1020-1032. doi: 10.1136/gutjnl-2021-326789.
17. Jin U.H., Lee S. O., Sridharan G., Lee K., Davidson L. A., Jayaraman A. et al. Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. Mol Pharmacol. 2014;85(5):777-88. doi: 10.1124/mol.113.091165.
18. Duseja A., Acharya S. K., Mehta M., Chhabra S., Shalimar R. S., Das A. et al. High Potency Multistrain Probiotic Improves Liver Histology in Non-Alcoholic Fatty Liver Disease (NAFLD): A Randomised, Double-Blind, Proof of Concept Study. BMJ Open Gastroenterol. 2019; 6: e000315. doi: 10.1136/bmjgast-2019-000315.
19. Modasia A., Parker A., Jones E., Stentz R., Brion A., Goldson A. et al. Regulation of Enteroendocrine Cell Networks by the Major Human Gut Symbiont Bacteroides thetaiotaomicron. Front Microbiol. 2020;11:575595. doi: 10.3389/fmicb.2020.575595.
20. Hernández-Granados MJ, Franco-Robles E. Postbiotics in human health: Possible new functional ingredients? Food Research International. 2020; 137:109660. doi: 10.1016/j.foodres.2020.109660.
Review
For citations:
Dudanova O.P., Larina N.A., Shipovskaya A.A., Kurbatova I.V. Efficacy of the Bactimunal metabiotic (based on Bacillus subtilis) in non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2023;(8):93-99. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-216-8-93-99
Views:
564
Email this article 